Covered recipient · General Payments record
MICHAEL W MESHAD
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$1,677.09
101 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,601.10 | 100 |
| Education | $75.99 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $277.82 | 14 |
| Novartis Pharmaceuticals Corporation | $208.59 | 11 |
| E.R. Squibb & Sons, L.L.C. | $121.68 | 10 |
| Amgen Inc. | $106.78 | 7 |
| Merck Sharp & Dohme Corporation | $106.13 | 6 |
| AstraZeneca Pharmaceuticals LP | $86.62 | 6 |
| Eisai Inc. | $79.38 | 4 |
| Epizyme, Inc., | $72.73 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $62.11 | 4 |
| Incyte Corporation | $62.08 | 4 |
| PFIZER INC. | $57.41 | 4 |
| Daiichi Sankyo Inc. | $53.96 | 3 |
| Acceleron Pharma, Inc. | $51.61 | 3 |
| BeiGene USA, Inc. | $50.75 | 4 |
| GlaxoSmithKline, LLC. | $36.06 | 2 |
| Janssen Biotech, Inc. | $30.62 | 2 |
| Dova Pharmaceuticals | $29.93 | 2 |
| Genentech USA, Inc. | $29.85 | 2 |
| Ipsen Biopharmaceuticals, Inc | $25.50 | 1 |
| Karyopharm Therapeutics Inc. | $24.53 | 2 |
| Seagen Inc. | $19.43 | 1 |
| Regeneron Healthcare Solutions, Inc. | $19.40 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $14.71 | 1 |
| Lexicon Pharmaceuticals, Inc. | $13.49 | 1 |
| Deciphera Pharmaceuticals Inc. | $12.28 | 1 |
| Rigel Pharmaceuticals, Inc. | $11.96 | 1 |
| Secura Bio, Inc. | $11.68 | 1 |
Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL W MESHAD
NPI 1538112701 · CMS profile ID 606062
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
MOBILE, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL W MESHAD, NPI 1538112701, CMS profile ID 606062. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). MICHAEL W MESHAD, NPI 1538112701, CMS profile ID 606062. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- MICHAEL W MESHAD, NPI 1538112701, CMS profile ID 606062, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
101 matching records · $1,677.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–101 of 101.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $23.00 | 01/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739475595 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,233,354.80 | 407 |
| PY2024 | Principal investigator | $642,244.87 | 184 |
| PY2023 | Principal investigator | $530,609.62 | 245 |
| PY2022 | Recipient | $10,000.00 | 12 |
| PY2022 | Principal investigator | $559,598.18 | 92 |
| PY2021 | Recipient | $32.00 | 1 |
| PY2021 | Principal investigator | $735,462.12 | 172 |
| PY2020 | Principal investigator | $625,066.99 | 292 |
| PY2019 | Principal investigator | $972,624.38 | 222 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
407 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $564.36 | 12/31/2025 | Non-covered Recipient Entity Southern Cancer Center SCC | KEYMAKER-U01 Substudy 01E# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II IIIB N2 Non-small Cell | No dispute reported | 06/30/2026 | 1232924952 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,402.83 | 12/31/2025 | Non-covered Recipient Entity Southern Cancer Center, PC | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232927171 |
| Principal investigator 1 | Incyte Corporation | $3,375.00 | 12/29/2025 | Non-covered Recipient Entity SOUTHERN CANCER CTR DAPHNE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240591775 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $2,835.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753338 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,510.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753340 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 12/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388247 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 12/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388249 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388253 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 12/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,252.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175326905 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388237 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388243 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388251 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388257 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $2,835.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753222 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,240.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753336 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $1,620.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753342 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388239 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388241 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $74,426.18 | 12/05/2025 | Non-covered Recipient Entity Coastal Pharmacy, Llc | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235997962 |
| Principal investigator 1 | Eli Lilly and Company | $1,110.00 | 12/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187890608 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,360.00 | 11/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387471 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,750.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185537441 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327596 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328386 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 11/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387469 |
| Principal investigator 1 | Epizyme, Inc. | $390.00 | 11/10/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281602 |
| Principal investigator 1 | Epizyme, Inc. | $390.00 | 11/10/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281604 |
| Principal investigator 1 | Epizyme, Inc. | $390.00 | 11/10/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281606 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388227 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388229 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388231 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388233 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 11/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388235 |
| Principal investigator 1 | Epizyme, Inc. | $1,125.00 | 11/05/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281608 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388141 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $301.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388155 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388159 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388165 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388177 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388179 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388191 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388195 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388213 |
| Principal investigator 1 | Genentech, Inc. | $19,949.00 | 10/24/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680953 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/24/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680971 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $588.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387459 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $82.60 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,416.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387463 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 10/23/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388127 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383862 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 10/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CTR DAPHNE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240591780 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 10/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 10/14/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387455 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/14/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387457 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $412.00 | 10/14/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/14/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388147 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387467 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388133 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388145 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388149 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $900.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388151 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388157 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $987.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388161 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388163 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388167 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388169 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388171 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388173 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388175 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388181 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388183 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388185 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388189 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388193 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388203 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388215 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388217 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388219 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388221 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388223 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388225 |
| Principal investigator 1 | Genentech, Inc. | $53.00 | 10/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680967 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 09/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753942 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 09/10/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Polarix | No dispute reported | 06/30/2026 | 1211681278 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 09/10/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Polarix | No dispute reported | 06/30/2026 | 1211681284 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 09/10/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Polarix | No dispute reported | 06/30/2026 | 1211681336 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 09/10/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Polarix | No dispute reported | 06/30/2026 | 1211681346 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388125 |
| Principal investigator 1 | Epizyme, Inc. | $1,125.00 | 09/04/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281306 |
| Principal investigator 1 | Genentech, Inc. | $29,358.00 | 09/03/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211677474 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $885.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387449 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387451 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,078.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387453 |
| Principal investigator 1 | Genentech, Inc. | $861.00 | 08/22/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680433 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327109 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940148 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940164 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940171 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940177 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940190 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940200 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940209 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940224 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940237 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940248 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940262 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940272 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940282 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940293 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940305 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940316 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940326 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940342 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940353 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940365 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940406 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940431 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940449 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940467 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940476 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940492 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940504 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940516 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 08/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940526 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 08/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754192 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $490.00 | 08/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387447 |
| Principal investigator 1 | Genentech, Inc. | $511.00 | 08/06/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680513 |
| Principal investigator 1 | Genentech, Inc. | $14,650.00 | 08/04/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211677419 |
| Principal investigator 1 | Genentech, Inc. | $26,384.00 | 08/04/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211677451 |
| Principal investigator 1 | Genentech, Inc. | $173.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680279 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680307 |
| Principal investigator 1 | Genentech, Inc. | $2,093.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680331 |
| Principal investigator 1 | Genentech, Inc. | $319.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680361 |
| Principal investigator 1 | Genentech, Inc. | $536.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680413 |
| Principal investigator 1 | Genentech, Inc. | $536.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680463 |
| Principal investigator 1 | Genentech, Inc. | $536.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680471 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680527 |
| Principal investigator 1 | Genentech, Inc. | $2,022.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680567 |
| Principal investigator 1 | Genentech, Inc. | $70.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680739 |
| Principal investigator 1 | Genentech, Inc. | $373.00 | 08/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,000.00 | 07/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327184 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $411.79 | 07/28/2025 | Non-covered Recipient Entity Coastal Pharmacy, Llc | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235997964 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680327 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680449 |
| Principal investigator 1 | Genentech, Inc. | $23,095.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680481 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680551 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680555 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680629 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680675 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 07/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680825 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $32,750.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185537443 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753540 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 07/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CTR DAPHNE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240591771 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940381 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940394 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940418 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175329086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 06/19/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387445 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753350 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 06/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940553 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 06/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940582 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 06/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940900 |
| Principal investigator 1 | ABBVIE INC. | $1,094.86 | 05/16/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202485379 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,240.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753104 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $2,835.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753108 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $2,835.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753110 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $1,620.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753132 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $230.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753134 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387443 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388279 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388281 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388283 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388285 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388287 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388289 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $412.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388291 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,416.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $82.60 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388295 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388297 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $177.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388299 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,360.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388301 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 05/15/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223388303 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940541 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940564 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940605 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940618 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940643 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940655 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940666 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940678 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940686 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940715 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940766 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940775 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940788 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940801 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940812 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940823 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940841 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940859 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940872 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940887 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940915 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940926 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 05/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940953 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 05/14/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680007 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 05/08/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388305 |
| Principal investigator 1 | Genentech, Inc. | $13,562.00 | 05/08/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211677205 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $92,628.70 | 05/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185537433 |
| Principal investigator 1 | Genentech, Inc. | $3,742.00 | 05/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211680175 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,650.00 | 04/30/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185537429 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $101,288.61 | 04/30/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185537437 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,050.00 | 04/30/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185537439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 04/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388121 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,282.00 | 04/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388123 |
| Principal investigator 1 | ABBVIE INC. | $5,518.28 | 04/23/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202478724 |
| Principal investigator 1 | ABBVIE INC. | $1,250.00 | 04/18/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202478129 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 04/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $588.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387441 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388119 |
| Principal investigator 1 | ABBVIE INC. | $1,063.00 | 04/15/2025 | Non-covered Recipient Entity COASTAL PHARMACY-ORALS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202476618 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383860 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 04/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CTR DAPHNE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240591764 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 04/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CTR DAPHNE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240591767 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940728 |
| Principal investigator 1 | Epizyme, Inc. | $2,557.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280928 |
| Principal investigator 1 | Epizyme, Inc. | $3,539.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184280988 |
| Principal investigator 1 | Epizyme, Inc. | $1,958.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281004 |
| Principal investigator 1 | Epizyme, Inc. | $1,596.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281034 |
| Principal investigator 1 | Epizyme, Inc. | $2,145.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281038 |
| Principal investigator 1 | Epizyme, Inc. | $1,005.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281052 |
| Principal investigator 1 | Epizyme, Inc. | $1,005.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281128 |
| Principal investigator 1 | Epizyme, Inc. | $1,831.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281150 |
| Principal investigator 1 | Epizyme, Inc. | $2,076.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281152 |
| Principal investigator 1 | Epizyme, Inc. | $2,785.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281160 |
| Principal investigator 1 | Epizyme, Inc. | $1,958.00 | 04/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388083 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388117 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 03/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Polarix | No dispute reported | 06/30/2026 | 1211681242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388033 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388053 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388057 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388107 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388113 |
| Principal investigator 1 | Amgen Inc. | $1,500.15 | 03/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | No dispute reported | 06/30/2026 | 1246648422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 03/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383982 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940594 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940630 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940701 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174940752 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388041 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388047 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388055 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388081 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388087 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388091 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388095 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388103 |
| Principal investigator 1 | Genentech, Inc. | $1,475.00 | 03/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679813 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 03/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679849 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388029 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388031 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388035 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388037 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388039 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388043 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388045 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388049 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388051 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388061 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388065 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388067 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388069 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388071 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388073 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $302.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388075 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388079 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $211.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388085 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388089 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,415.13 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388093 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388097 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $368.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388099 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388109 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,416.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388111 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $301.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $150.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,047.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $70.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383878 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383880 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,006.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383884 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,204.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383890 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $752.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383894 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,515.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $350.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383902 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383946 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,749.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $56.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $201.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 02/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387191 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,014.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387193 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,915.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387195 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,200.00 | 02/11/2025 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER | No dispute reported | 06/30/2026 | 1235992209 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 01/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754182 |
| Principal investigator 1 | Genentech, Inc. | $4,847.00 | 01/22/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211679869 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $338.35 | 01/21/2025 | Covered Recipient Teaching Hospital Ascension Sacred Heart Pensacola | A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible | No dispute reported | 06/30/2026 | 1236001809 |
| Principal investigator 1 | Eli Lilly and Company | $119,574.00 | 01/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187891996 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $142,228.92 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185537431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,733.00 | 01/16/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388277 |
| Principal investigator 1 | ABBVIE INC. | $1,063.00 | 01/15/2025 | Non-covered Recipient Entity COASTAL PHARMACY-ORALS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202438599 |
| Principal investigator 1 | Amgen Inc. | $516.77 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | MyLung Consortium Study (USOR) | No dispute reported | 06/30/2026 | 1246648428 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,860.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 1185537435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,874.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223383866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $56.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,039.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383950 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,415.13 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383952 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383956 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383960 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $383.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383964 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383966 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383968 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $56.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383970 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383994 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $935.00 | 01/15/2025 | Non-covered Recipient Entity Southern Cancer Center | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER | No dispute reported | 06/30/2026 | 1235993583 |
| Principal investigator 1 | Eli Lilly and Company | $114,463.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187888100 |
| Principal investigator 1 | Eli Lilly and Company | $2,383.30 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | Not supplied | No dispute reported | 06/30/2026 | 1187889674 |
| Principal investigator 1 | Eli Lilly and Company | $4,221.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187891356 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER-DAPHNE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240591761 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 01/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940739 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 01/15/2025 | Non-covered Recipient Entity Southern Cancer Center | MYLUNG Consortium Study Protocol 2 (MYLUNG) | No dispute reported | 06/30/2026 | 1174940937 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,063.00 | 01/15/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | Clinical trial to assess the efficacy and safety of an alternative dosing regimen of ribociclib in breast cancer | No dispute reported | 06/30/2026 | 1190303823 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753344 |
| Principal investigator 1 | Eli Lilly and Company | $2.67 | 01/07/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187891324 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/03/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/03/2025 | Non-covered Recipient Entity SOUTHERN CANCER CENTER, P.C. | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223383996 |